172 related articles for article (PubMed ID: 14612455)
1. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis.
Steinman HA; Burstein E; Lengner C; Gosselin J; Pihan G; Duckett CS; Jones SN
J Biol Chem; 2004 Feb; 279(6):4877-86. PubMed ID: 14612455
[TBL] [Abstract][Full Text] [Related]
2. Tumor promotion by Mdm2 splice variants unable to bind p53.
Fridman JS; Hernando E; Hemann MT; de Stanchina E; Cordon-Cardo C; Lowe SW
Cancer Res; 2003 Sep; 63(18):5703-6. PubMed ID: 14522887
[TBL] [Abstract][Full Text] [Related]
3. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.
Sigalas I; Calvert AH; Anderson JJ; Neal DE; Lunec J
Nat Med; 1996 Aug; 2(8):912-7. PubMed ID: 8705862
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis.
Jones SN; Hancock AR; Vogel H; Donehower LA; Bradley A
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15608-12. PubMed ID: 9861017
[TBL] [Abstract][Full Text] [Related]
5. Regulation of human p53 activity and cell localization by alternative splicing.
Ghosh A; Stewart D; Matlashewski G
Mol Cell Biol; 2004 Sep; 24(18):7987-97. PubMed ID: 15340061
[TBL] [Abstract][Full Text] [Related]
6. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma.
Bartel F; Meye A; Würl P; Kappler M; Bache M; Lautenschläger C; Grünbaum U; Schmidt H; Taubert H
Int J Cancer; 2001 May; 95(3):168-75. PubMed ID: 11307150
[TBL] [Abstract][Full Text] [Related]
7. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
[TBL] [Abstract][Full Text] [Related]
8. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
10. Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair.
Alt JR; Bouska A; Fernandez MR; Cerny RL; Xiao H; Eischen CM
J Biol Chem; 2005 May; 280(19):18771-81. PubMed ID: 15734743
[TBL] [Abstract][Full Text] [Related]
11. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
12. Mdm2: A regulator of cell growth and death.
Vargas DA; Takahashi S; Ronai Z
Adv Cancer Res; 2003; 89():1-34. PubMed ID: 14587869
[TBL] [Abstract][Full Text] [Related]
13. Amplification of a gene encoding a p53-associated protein in human sarcomas.
Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B
Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537
[TBL] [Abstract][Full Text] [Related]
14. MDMX: a novel p53-binding protein with some functional properties of MDM2.
Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
Fan C; Wang X
Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
[TBL] [Abstract][Full Text] [Related]
16. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.
Matsumoto R; Tada M; Nozaki M; Zhang CL; Sawamura Y; Abe H
Cancer Res; 1998 Feb; 58(4):609-13. PubMed ID: 9485008
[TBL] [Abstract][Full Text] [Related]
17. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
18. Alternative and aberrant splicing of MDM2 mRNA in human cancer.
Bartel F; Taubert H; Harris LC
Cancer Cell; 2002 Jul; 2(1):9-15. PubMed ID: 12150820
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
Tamborini E; Della Torre G; Lavarino C; Azzarelli A; Carpinelli P; Pierotti MA; Pilotti S
Int J Cancer; 2001 Jun; 92(6):790-6. PubMed ID: 11351297
[TBL] [Abstract][Full Text] [Related]
20. Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs.
Liang H; Atkins H; Abdel-Fattah R; Jones SN; Lunec J
Gene; 2004 Sep; 338(2):217-23. PubMed ID: 15315825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
